Why is BioNTech stock sliding today?

BioNTech SE shares slipped 1.2% in pre-market trading to $102.55 on Tuesday, pressured by a significant analyst downgrade that reinforced existing concerns about the company's near-term revenue outlook. BMO Capital Markets lowered its rating on the stock from Outperform to Market Perform and cut its price target to $105 from $128, citing softer global demand for COVID vaccines and an ongoing inventory drawdown in Germany as the main reasons for its more cautious stance. The firm's long-term projections for Comirnaty steady-state revenue are materially below the broader consensus among analysts, signaling a structural reassessment rather than a simple near-term adjustment.

The downgrade adds to a challenging period for the stock that began in late August, when BioNTech announced the discontinuation of its Phase 2 trial of autogene cevumeran in resected colorectal cancer. That decision, made jointly with Roche's Genentech unit after the study crossed a futility threshold, weakened investor confidence in the company's personalized mRNA cancer-vaccine strategy and removed a closely watched clinical catalyst. Separately, BioNTech cut its full-year 2026 revenue guidance to a range of €1.6 billion to €1.9 billion, down from an earlier range of €2.0 billion to €2.3 billion, and analysts have since trimmed consensus revenue and loss-per-share estimates.

The broader market is providing little relief today, with S&P 500 futures down 0.3% and Nasdaq futures slightly lower by 0.1% in pre-market trading, creating a mild risk-off backdrop that tends to magnify moves in high-beta, loss-making biotech stocks. BNTX has a beta above 1, meaning it has historically been more volatile than the index in both directions; with no dividend cushion and ongoing R&D investment, changes in sentiment carry outsized weight on the share price.

Taken together, BMO's downgrade crystallizes a narrative that has been developing since BioNTech's second-quarter results: the post-COVID revenue decline is proving steeper and more persistent than the market had incorporated, while the oncology pipeline—though broad, with 14 pivotal trials underway—has yet to deliver the commercial validation needed to fully offset that headwind. With shares trading around $102.55, only slightly below BMO's new $105 target, the downgrade effectively signals limited near-term upside from one of the stock's previously bullish voices.

This article was generated with the support of AI and reviewed by an editor. For more information, please see our Terms & Conditions.